哪些患者报告泌尿外科医生建议其放弃前列腺癌初始治疗
基于2014至2015年新诊断局限性前列腺癌男性的调查(校正应答率51.3%),约62.2%低危肿瘤患者和46.4%预期寿命有限者报告泌尿外科医生建议放弃根治性治疗。在预期寿命有限者中,低危肿瘤患者比高危者更可能收到该建议(OR 3.41;95%CI 2.17-5.37)。低危患者收到建议后接受根治性治疗的可能性更低(OR 0.48;95%CI 0.32-0.73),但感知的癌症照护质量未降低(OR 0.97;95%CI 0.63-1.48)。
要点
- 多数低危前列腺癌患者报告泌尿外科医生建议放弃根治性初始治疗。
- 预期寿命有限者中,低危肿瘤比高危肿瘤更易收到放弃根治性治疗建议。
- 该建议与低危患者更少接受根治性治疗相关,且未降低感知照护质量。
核心结论
- 多数低危前列腺癌男性报告泌尿外科医生建议放弃根治性初始治疗。
- 泌尿外科医生对患者治疗选择有较强影响,或可在适合期待管理的男性中提高主动监测采用率而不降低患者感知的照护质量。
研究设计与样本
- 基于人群的调查研究,向2014至2015年新诊断局限性前列腺癌男性邮寄问卷,校正应答率51.3%。
- 使用logistic回归模型评估患者层面预测因素及建议与治疗选择、感知照护质量的关联。
主要发现
- 62.2%的低危肿瘤男性报告泌尿外科医生建议放弃根治性治疗。
- 46.4%的预期寿命有限男性报告该建议。
- 预期寿命有限者中,低危肿瘤比高危肿瘤更可能收到该建议(OR 3.41;95%CI 2.17-5.37)。
- 低危肿瘤患者收到建议后接受根治性治疗的可能性更低(OR 0.48;95%CI 0.32-0.73)。
- 低危肿瘤患者收到建议与感知照护质量无显著关联(OR 0.97;95%CI 0.63-1.48)。
关键数值与推荐
- 低危肿瘤患者报告放弃根治性治疗建议的比例为62.2%。
- 预期寿命有限患者报告该建议的比例为46.4%。
- 预期寿命有限者中低危对比高危肿瘤收到建议的OR为3.41(95%CI 2.17-5.37)。
- 低危肿瘤患者收到建议与接受根治性治疗的OR为0.48(95%CI 0.32-0.73)。
- 低危肿瘤患者收到建议与感知照护质量的OR为0.97(95%CI 0.63-1.48)。
临床怎么用
- 泌尿外科医生应意识到自身建议对前列腺癌初始治疗选择的强影响。
- 对适合期待管理的低危患者,可积极沟通放弃根治性治疗或主动监测的选项。
- 提供放弃根治性治疗建议时无需担心降低患者感知的癌症照护质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine how frequently patients report that their urologist recommended forgoing definitive treatment and assess the impact of these recommendations on treatment choice and perceived quality of cancer care. METHODS: We mailed surveys to men newly diagnosed with localized prostate cancer between 2014 and 2015 (adjusted response rate of 51.3%). Men reported whether their urologist recommended forgoing definitive treatment. Using logistic regression models, we assessed patient-level predictors of receiving a recommendation to forgo definitive treatment and estimated associations of receiving this recommendation with receipt of definitive treatment and perceived quality of cancer care among men with low-risk tumors and limited life expectancies. RESULTS: Nearly two-thirds (62.2%) of men with low-risk tumors and 46.4% with limited life expectancies received recommendations from their urologists to forgo definitive treatment. Among men with limited life expectancies, those with low-risk tumors were more likely to receive this recommendation compared with men with high-risk tumors (odds ratio [OR] 3.41; 95% confidence interval [CI] 2.17-5.37). Men with low-risk tumors who were recommended to forgo definitive treatment were less likely to receive definitive treatment (OR 0.48; 95% CI 0.32-0.73) but did not report lower perceived quality of care (OR 0.97; 95% CI 0.63-1.48). CONCLUSION: In this population-based study, a majority of men with low-risk prostate cancer report receiving recommendations from their urologists to forgo definitive treatment. Our results suggest that urologists have a strong influence on patient treatment choice and could increase active surveillance uptake in men eligible for expectant management without patients perceiving lower quality of cancer care.
引用
- Radhakrishnan A, Grande D, Mitra N, et al. Which Patients Report That Their Urologists Advised Them to Forgo Initial Treatment for Prostate Cancer? Urology. 2018. PMID: 29477313. doi:10.1016/j.urology.2018.01.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。